Liccardi, Gianmaria - assoc. RG 43

Introduction

Our work focuses on the interplay between cell death and inflammation and its ability to shape tissue homeostasis and pathophysiological diseases. Importantly, we are interested in understanding how genetic instability further modulates this relationship and how this impacts the development and treatment of different cancer entities. Our lab comprises international and national scientists and we support equality for every gender (including LGBTQIAX), religion and race. We stand strong on the principle of scientific integrity and professional conduct as well as with the intent of creating an intercative and collaborative environment where students and staff can excel maintaining a healthy mental, personal and professional balance. 

Lab Website

For more information, please check Liccardi Lab.

Affiliations

 

Publication Record on PubMed - Gianmaria Liccardi

2024
  • Albert MC, Uranga-Murillo I, Arias M, De Miguel D, Pena N, Montinaro A, Varanda AB, Theobald SJ, Areso I, Saggau J, Koch M, Liccardi G, Peltzer N, Rybniker J, Hurtado-Guerrero R, Merino P, Monzon M, Badiola JJ, Reindl-Schwaighofer R, Sanz-Pamplona R, Cebollada-Solanas A, Megyesfalvi Z, Dome B, Secrier M, Hartmann B, Bergmann M, Pardo J, and Walczak H (2024). Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality. Cell Death Differ. doi:10.1038/s41418-024-01278-6.
     
  • Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Fernandez LT, Saggau J, Bonasera D, Kiljan M, Gozum G, Lichius L, Cai J, Niu LN, Caiaffa MI, Herter JM, Walczak H, Liccardi G, Grüll H, Büttner R, Bosco G, George J, Thomas RK, Bozek K, Reinhardt HC, Herter-Sprie GS. A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. J Cancer Res Clin Oncol. 2024 Nov 14;150(11):496. doi: 10.1007/s00432-024-05942-9. PMID: 39542886; PMCID: PMC11564195.
     
  • Imai T, Lin J, Kaya GG, Ju E, Kondylis V, Kelepouras K, Liccardi G, Kim C, andPasparakis M (2024). The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. Immunity. doi:10.1016/j.immuni.2024.04.016.
     
  • Kelepouras K, Saggau J, Varanda AB, Zrilic M, Kiefer C, Rakhsh-Khorshid H, Lisewski I, Uranga-Murillo I, Arias M, Pardo J, Tonnus W, Linkermann A, Annibaldi A, Walczak H, Liccardi G. The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo. Cell Death Differ. 2024 Jul;31(7):897-909. doi: 10.1038/s41418-024-01313-6. Epub 2024 May 23. PMID: 38783091; PMCID: PMC11239901.
     
  • Kelepouras K, Saggau J, Varanda AB, Zrilic M, Kiefer C, Rakhsh-Khorshid H, Lisewski I, Uranga-Murillo I, Arias M, Pardo J, Tonnus W, Linkermann A, Annibaldi A, Walczak H, and Liccardi G (2024). The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo. Cell Death Differ. doi:10.1038/s41418-024-01313-6.
     
  • Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, Kreko M, Azami S, Montinaro A, Wang Y, Nikolov V, Kaiser L, Bonasera D, Saggau J, Scholz T, Schmitt A, Beleggia F, Reinhardt HC, George J, Liccardi G, Walczak H, Tovari J, Bragelmann J, Montero J, Sos ML, Orfi L, and Peltzer N (2024). CDK9 inhibition as an effective therapy for small cell lung cancer. Cell Death Dis15, 345. doi:10.1038/s41419-024-06724-4.

 

Discover more: